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abstRact
IntroductIon: Many acutely ill elderly people are frail and 
suffer from polypharmacy. They often present with nonspe-
cific symptoms at hospital admission and are therefore of-
ten under-triaged and insufficiently treated resulting in ad-
verse health outcomes. This study aimed to investigate the 
prevalence of polypharmacy and frailty and to identify if 
frailty and polypharmacy may predict adverse health out-
comes in elderly patients who are acutely admitted to hos-
pital. 
Methods: The study was a descriptive cohort study includ-
ing patients ≥ 65 years acutely admitted to hospital during 
a 14-day period, n = 250. The included patients were as-
sessed for frailty, and the total number of health problems 
requiring treatment, geriatric problems and medication 
were registered. 
results: Frail patients suffering from polypharmacy had 
significantly more health problems, 13-fold longer hospital 
stays, they were more often discharged to nursing homes 
and had a five times greater risk of readmission than pa-
tients without frailty and polypharmacy. Polypharmacy was 
present in 62% and hyper-polypharmacy in 20% of the pa-
tients, and frailty was present in 85% of the patients with 
polypharmacy and in 40% of those without polypharmacy. 
conclusIon: Compared with non-frail patients without 
polypharmacy, frail elderly patients with polypharmacy be-
long to a high-risk group and should receive an immediate 
geriatric assessment and treatment including long-term 
planning by the Mobile Geriatric Team. 
FundIng: none.
trIal regIstratIon: The study was approved and regis-
tered with the Danish Data Protection Agency under the 
Capital Region of Denmark’s joint notification of health re-
search (j. no.: 2007-58-0015, AMH-2013-003, I-Suite no: 
02495).
The prevalence of diseases like hypertension, heart dis-
ease, stroke, diabetes, osteoporosis and dementia is 
high in the elderly population and multi-morbidity is 
present in up to 98% [1]. As many diseases require treat-
ment with medication, elderly people are likely to suffer 
from polypharmacy. In Denmark, 60% of the resident 
population of > 75 year olds use > 3 and 33% use > 5 
medications [2]. The use of several different medications 
and age-related changes in pharmacokinetics and phar-
macodynamics often result in adverse drug events, drug 
interactions and increased morbidity [3].
The term polypharmacy is used ambiguously. In 
some studies, elderly people’s use of ≥ 3 different med-
ications on a daily basis is defined as polypharmacy [4], 
whereas other studies define polypharmacy as long-
term use of ≥ 2 medications [5]. The results from a 
study by Gnjidic et al, including 1,705 older men, sup-
port the definition of polypharmacy as the use of ≥ 5 
medications on a daily basis. Thus, an association was 
found between the use of 6.5 medications and frailty, 
5.5 and disability and mortality, and the use of 4.5 medi-
cations and falls. They also found that, when the num-
ber of medication increases by one the risk of being frail 
increases by 27% (odds ratio (OR) = 1.27; 95% confi-
dence interval (CI): 1.20-1.34) and the risk of early death 
increases by 15% (OR = 1.15; 95% CI: 1.11-1.20) [6]. Falls 
have also been associated with use of medications, and 
Neutel et al found a six times greater risk of falls for indi-
viduals with hyper-polypharmacy [7]. 
Reviewing the patients’ medication is often seen as 
a key element in reducing inappropriate prescribing and 
thus in reducing adverse health outcomes, but a recent 
Cochrane review was unable to establish significant evi-
dence on the effect of medication reviews for hospital-
ised old people. This may be because of an unclear defi-
nition of the high-risk patients who were comprised by 
the review [8]. One way of defining high-risk patients is 
by using the concept of frailty described as a condition 
of diminished tolerance of stress associated with a high 
prevalence of adverse health outcomes including both 
physical and cognitive decline, falls, institutionalisation 
and mortality [9]. In an earlier study, we found that two-
thirds of acutely admitted elderly patients were frail 
[10].
In frail elderly people, further changes in their re-
sponses to medication will occur, and an even greater 
risk of adverse drug events may be observed [11]. Thus, 
it seems that both polypharmacy and frailty are factors 
that should be taken into consideration when elderly pa-
tients are assessed in the emergency department (ED) or 
the acute medical unit (AMU).
The primary aim of the present study was to identi-
fy if frailty and polypharmacy could predict long hospital 
stay, institutionalisation, readmission and death in pa-
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tients aged > 65 years who were admitted to the ED or 
AMU. The secondary aim was to describe the prevalence 
of polypharmacy and hyper-polypharmacy specifically in 
patients suffering from the following geriatric problems: 
cognitive impairment, depression, delirium, malnutri-
tion, pain and falls. 
mEthOds
This was a descriptive cohort study. During a 14-day pe-
riod in January 2013, all patients admitted to the ED/
AMU of Amager Hospital, Denmark, aged ≥ 65 years 
were included, regardless of diagnosis. Excluded were 
patients who were admitted from nursing homes due to 
a high Identification of Seniors at Risk (ISAR) score, as 
we expected that their inclusion might have biased the 
results.
We used the ISAR screening tool to identify frail el-
derly patients [12]. ISAR consists of six questions to pre-
dict functional decline and other adverse outcomes after 
an ED stay. The answers were Yes/No and scores ranged 
from zero to six points; at a score of ≥ 2 patients were 
considered frail and at risk of readmission and/or loss of 
function.
The Mobile Geriatric Team ISAR screened all includ-
ed patients admitted to the ED/AMU. 
Data on patient characteristics were extracted from 
the medical records and included age, sex, number of 
medications at discharge, length of stay, discharge to 
nursing home or rehabilitation (nursing home), readmis-
sion and mortality. From the medical records, the senior 
geriatrician assessed the patients’ geriatric problems de-
fined as cognitive impairment, depression, delirium, 
malnutrition, pain and falls, and the total number of 
health problems that needed treatment such as acute 
infections, dehydration, electrolyte balance, acute exac-
erbation of chronic obstructive pulmonary disease and 
continued treatment of chronic diseases like diabetes, 
heart disease and osteoporosis. Because of the patients’ 
multi-morbidity, the total number of health problems 
was used rather than the primary discharge diagnoses. 
At the time of assessment, the ISAR score was blinded to 
the senior geriatrician.
Polypharmacy was defined as a prescribed regular 
daily intake of five or more medications. As earlier stud-
ies have found that daily use of multivitamins, vitamin D 
and calcium preparations increased the risk of falling [7], 
these supplements were included. Temporarily pre-
scribed medications such as antibiotics were not includ-
ed. Hyper-polypharmacy was defined as a prescribed 
regular daily intake of ten or more medications. 
statistical analyses
Patient characteristics are presented as means with 
standard deviation (SD) and as proportions. 
Differences in patients with polypharmacy versus 
those without were assessed using chi-squared for cate-
gorical variables and the t-test for comparison of means. 
With the independent variables of interest being frailty 
and polypharmacy, the dependent variables were days 
in hospital, health problems, readmission, admission to 
nursing home and death. Adjusted results were calculat-
ed using backward stepwise logistic regression concern-
ing the potential covariates age, sex and symptoms of 
depression, delirium, pain, fall and nutrition. Multiva-
riate comparisons were made using logistic or linear re-
gression. A p-value < 0.05 was considered significant. All 
statistical procedures were performed using SPSS for 
Windows, version 14.0 (SPSS Inc., Chicago, IL, USA).
Trial registration: The study was approved and regis-
tered with the Danish Data Protection Agency under the 
Capital Region of Denmark’s joint notification of health 
research (j. no.: 2007-58-0015, AMH-2013-003, I-Suite 
no: 02495).
REsUlts 
During the inclusion period, 250 patients aged ≥ 65 
years were admitted to the ED/AMU. Information on 
medication at discharge was available for 219 patients 
of whom 189 were ISAR screened. We found no differ-
ence in sex, age or mean number of health problems in 
patients with information on medication at discharge 
compared with those without such information. The 
mean number of medications was six (SD: ± 4.13). Polyp-
harmacy was present in 135 (62%) among whom the 
mean number of medication was 8.6 (SD: ± 3.34); and 
hyper-polyphar macy was found in 43 (20%) among 
whom the mean number of medications was 12.5 (SD: ± 
2.88). Fifteen (7%) patients were discharged without any 
prescribed me dications and 12 (6%) were treated with a 
single me dication only. The distribution of medications 
at different ISAR scores is shown in table 1. Of the 189 
ISAR-screened patients, 127 (67%) were found to be frail 
tablE 1
Distribution of medications on ISAR score (N = 219).
isaR score n mean (95% ci) ± sd min. max.
0 24 1.21 (0.71-1.71) ± 1.18 0 4
1 38 4.95 (3.99-5.90) ± 2.91 0 12
2 42 5.74 (4.80-6.67) ± 3.01 0 13
3 43 8.12 (6.84-9.39) ± 4.14 0 17
4 26 8.38 (6.87-9.90) ± 3.75 4 17
5 12 8.33 (6.26-10.40) ± 3.26 3 15
6 4 14.50 (2.56-26.44) ± 7.51 8 24
CI = confidence interval; ISAR = Identification of Seniors at Risk; SD = 
standard deviation.
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(Figure 1). Among these patients, 96 (51%) suffered 
from pain, 66 (35%) from falls, 43 (23%) from depres-
sion, 31 (16%) from malnutrition and cognitive impair-
ment and ten (5%) from delirium (table 2).
We found an increased risk of polypharmacy for 
women versus men (68% versus 53%) with an OR of 1.96 
(95% CI: 1.13-3.41), p = 0.02. Patients with polyphar-
macy were significantly older than patients without (78 
versus 75 years, p = 0.01) and significantly more frail pa-
tients had polypharmacy (p = 0.00). 
Patients who were both frail and had polypharmacy 
also had significantly more health problems than pa-
tients without these two factors, 5.9 versus 2.7 p = 0.00. 
They also had a significantly longer stay in hospital, 
more discharges to nursing homes and a higher readmis-
sion rate at 30 and at 90 days (Table 2). Compared with 
non-frail patients with no polypharmacy, frail patients 
with polypharmacy were five times more likely to be re-
admitted at 30 days and almost eight times more likely 
to be admitted at 90 days. Adjusting for confounders 
made no difference (table 3). Pain was the only con-
founder with a significant effect on readmission (p = 
0.03). In patients who were either frail or who received 
polypharmacy, no difference in risk of readmission was 
found.
With respect to geriatric problems, we found that a 
significantly larger part of the patients who were both 
frail and had polypharmacy suffered from depression (p 
= 0.00), malnutrition (p = 0.02) and falls (p = 0.04) (Table 
2).
discUssiOn
In Emergency Medicine, most of the patients present 
with a complaint. If the symptom or complaint is spe-
cific, e.g. chest pain, the staff in the ED/AMU will enrol 
the patient into a well-defined management protocol. If, 
on the other hand, the patient arrives with nonspecific 
symptoms, they may be more likely not to receive im-
mediate attention. In a recent study by Djärv et al, it was 
found that patients presenting with only “decreased 
general condition” received a low triage priority and had 
a threefold increased risk of in-hospital death [13]. As 
many elderly patients present to the ED/AMU with non-
specific symptoms, it is thus important to identify those 
who are at risk to ensure that they undergo geriatric as-
sessment and receive help to prevent early death.
FigURE 1
Flow chart of 250 patients analysed with regard to medication and frailty.
No information on medication
(N = 31)
PP
(N = 135)
ISAR ≥ 2
(N = 98)
HPP
(N = 43)
ISAR ≤ 1
(N = 18)
ISAR ≥ 2
(N = 35)
HPP = hyper-polypharmacy; ISAR = Identiﬁcation of Seniors at Risk; PP = polypharmacy
ISAR ≤ 1
(N = 3)
ISAR ≥ 2
(N = 29)
ISAR ≤ 1
(N = 44)
No ISAR screen
(N = 19)
No ISAR screen
(N = 5)
No ISAR screen
(N = 11)
Medication 2-4
(N = 57)
Medication 1
(N = 12)
Medication 0
(N = 15)
Included (N = 250)
Information on medication
(N = 219)
ISAR screen
(N = 116)
ISAR screen
(N = 38)
ISAR screen
(N = 73)
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In our study we found that suffering from frailty 
and having polypharmacy significantly predicted length 
of stay, institutionalisation and readmission. Thus, to 
identify the elderly patients who must be offered geriat-
ric assessment, it makes sense to supplement the triage 
with screening for frailty and the number of medica-
tions. As sex, age, depression, delirium, pain, fall and 
malnutrition alone may predict an adverse outcome, we 
conducted confounding analyses for those dimensions. 
When including the confounders, we still found that 
frailty and polypharmacy significantly predicted readmis-
sion. No significance was found concerning death, prob-
ably because of the small number of included patients. 
From our results, we also see that the frail elderly pa-
tients with polypharmacy have six health problems on 
average. This underpins the fact that they are complex 
patients who require an immediate multidimensional 
and interdisciplinary effort such as a comprehensive  
geriatric assessment, which may increase the patients’ 
likelihood of remaining alive and staying in their own 
homes after an emergency admission to hospital [14]. 
For three of the geriatric problems (depression, falls 
and malnutrition), we found a significantly higher preva-
lence of both frailty and polypharmacy. This indicates 
that patients suffering from those problems are at par-
ticularly risk of suffering an adverse health outcome, 
why these patients require special attention in the ED/
AMU and should be offered comprehensive geriatric as-
sessment. 
The intervention directed towards polypharmacy 
should include a continuing plan for future reduction of 
medication and maintenance of the changes in medica-
tablE 2
Differences in health 
problems, length of stay, 
discharge destination,  
readmission and death 
relative to polypharmacy 
and frailty (N = 189).
non-PP +  
non-frail (n = 44)
non-PP + frail  
(n = 29)
PP + non-frail  
(n = 18)
PP + frail  
(n = 98) p-value
Length of stay, days, mean (± SD) 0.5 (± 1.37) 5.4 (± 6.62) 1.3 (± 2.85) 6.3 (± 7.82) 0.00
Discharged to nursing home, n (%) 0 (0) 5 (17) 1 (6) 17 (17) 0.02
Readmission within 30 days, n (%) (N = 187)a 4 (9) 5 (18) 3 (17) 32 (32) 0.01
Readmission within 90 days, n (%) (N = 182)b 5 (11) 7 (24) 5 (28) 47 (50) 0.00
Dead within 30 days, n (%) 0 (0) 1 (3) 0 (0) 1 (1) 0.52
Dead within 90 days, n (%) 0 (0) 4 (14) 0 (0) 3 (3) 0.11
Health problems, n, mean (± SD) 2.7 (± 1.98) 4.9 (± 2.19) 4.4 (± 1.81) 5.9 (± 2.63) 0.00
Geriatric problems 
Depression, n (%) (N = 43) 2 (5) 8 (18) 2 (5) 31 (72) 0.00
Cognitive impairment, n (%) (N = 31) 3 (10) 6 (19) 1 (3) 21 (68) 0.08
Malnutrition, n (%) (N = 31) 3 (10) 8 (26) 0 (0) 20 (64) 0.02
Pain, n (%) (N = 96) 22 (23) 12 (13) 7 (7) 55 (57) 0.37
Fall, n (%) (N = 66) 11 (17) 15 (23) 3 (4) 37 (56) 0.04
Delirium, n (%) (N = 10)   4 (40)   2 (20) 0   4 (40) 0.44
PP = polypharmacy; SD = standard deviation. 
a) As 2 patients either died or were not discharged within 30 days. 
b) As 7 patients either died or were not discharged within 90 days. 
tablE 3
Risk of readmission within 
30 and 90 days in patients 
relative to polypharmacy 
and frailtya (N = 189).
non PP + frail (n = 29) PP + non frail (n = 18) PP + frail (n = 98)
OR (CI 95%) p-value OR (CI 95%) p-value OR (CI 95%) p-value
Unadjusted model
Readmission 30 daysc 2.17 (0.53-8.92) 0.28 2.00 (0.40-10.01) 0.40 4.92 (1.62-14.96) 0.01
Readmission 90 daysd 2.87 (0.81-10.25) 0.10 3.00 (0.75-12.04) 0.12 7.80 (2.82-21.52) 0.00
Adjusted modelb
Readmission 30 daysc 2.27 (0.51-10.08) 0.28 1.67 (0.32-8.59) 0.54 5.04 (1.51-16.81) 0.01
Readmission 90 daysd 2.79 (0.67-11.56) 0.17 2.79 (0.67-11.56) 0.16 7.41 (2.49-22.07) 0.00
CI = confidence interval; OR = odds ratio; PP = polypharmacy. 
a) Non-frail patients not suffering from PP were chosen as reference group with OR = 1. 
b) Patient outcomes were adjusted for sex, age, depression, delirium, malnutrition, fall and pain. 
c) N = 187 as 2 patients either died or were not discharged within 30 days. 
d) N = 182 as 7 patients either died or were not discharged within 90 days.
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tion of the patient and it should involve the patient’s 
general practitioner (GP). This has been found to be 
challenging as studies have shown that only 64% of 
medication changes were maintained and only 42% of 
the newly prescribed medicines were implemented by 
primary care [15, 16]. Therefore, an important focus of 
the intervention plan must be information and accept-
ance from the patient and family as well as involvement 
of the GP. Furthermore, the information must include a 
precise explanation stating which medications are 
changed or discontinued and why. A well-proven guid-
ance that may be used to inform decisions to prescribe 
new or review existing medication is the STOPP/START 
criteria [17]. When using the STOPP/START criteria, a 9% 
reduction in adverse drug events and a three-day reduc-
tion in the length of stay were found, provided the crite-
ria were applied within the first 72 hours of admission 
[18]. In patients with polypharmacy, it is crucial to con-
sider the benefits against the potential harm for each 
medication, especially for preventive medication in pa-
tients with a diminished remaining life expectancy. 
Attention should focus not only on the number of medi-
cations, but also on the type of medications as it is 
known that very commonly used medications such as 
paracetamol and calcium preparations have side effects 
including an increased risk of falls in patients ≥ 65 years 
[19]. 
The limitations to our study include the relatively 
small number of patients in the assessed cohort due to 
practical limitations and the time available to us. Pro-
bably, as a result of this, we found no significant associa-
tion between frailty, polypharmacy and mortality. In ad-
dition, it would have been preferable if the study had 
been longitudinal. On the other hand, a strength of the 
study is the small number of excluded patients and the 
new knowledge produced concerning the significance of 
combining frailty and polypharmacy in predicting read-
mission of the patients within a short time after their 
discharge from hospital.
The findings of the present study suggest that initial 
triage in the ED/AMU must be supplemented with as-
sessment of both polypharmacy and frailty to ensure 
that frail patients are admitted. Thus, we suggest an im-
mediate comprehensive geriatric assessment carried out 
by the Mobile Geriatric Team of patients suffering from 
both frailty and polypharmacy. 
Today’s ED/AMU treatment seems to be aimed pri-
marily at the acute problems, and an early date of dis-
charge in itself often becomes the most important goal 
of the intervention. When frailty screening at admission 
is followed by assessment by the Mobile Geriatric Team, 
an early intervention is possible, including the prepara-
tion of a solid long-term plan for medication alterations 
that includes continued contact with the patients, their 
families and primary care to ensure the maintenance 
and any necessary changes to the plan.
The high rates of readmissions tells us very clearly 
that our plans for intervention at discharge from hospi-
tal fail for every other patient, and future studies are 
warranted to ascertain the possible effect of the de-
scribed geriatric assessment and intervention in the ED/
AMU followed by long-term intervention in cooperation 
with primary care. 
cOnclUsiOn 
In this study we found a high prevalence of polypharma-
cy in patients suffering from geriatric problems and es-
tablished that by using the ISAR instrument and combin-
ing it with observations on polypharmacy in the ED/
AMU we can predict a longer hospitalisation, greater risk 
of being discharged to institutions and readmission 
within 30 and 90 days. We therefore suggest that the tri-
age process in the ED/AMU is supplemented with frailty 
and polypharmacy screening.
Patients afflicted with both conditions should then 
be immediately assessed by the Mobile Geriatric Team 
who should draw up an intervention plan addressing the 
patient’s most pressing acute needs. The assessment 
should also include a robust long-term plan that should 
be accepted by both the patient and the family and 
which should involve primary care and include follow-up 
by the Mobile Geriatric Team to ensure that any needed 
alterations and maintenance of the plan were in place. 
The monitoring by the Mobile Geriatric Team should re-
main in place for more than 90 days to prevent readmis-
sion of the patient. 
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Combining the Identification of Seniors at Risk instrument with observations on polypharmacy in the 
emergency department/acute medical unit predicts a longer hospitalisation, greater risk of being dis-
charged to institutions and readmission.
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